Umeå-based Lipum will reach an important milestone in its history this year as clinical trials begin on its antibody to treat inflammatory diseases. No less than 17 consultants are now involved in the drug’s development.
Swedish biotech company Agrisera has nearly doubled its workforce in the past two years, having recently moved to new and larger premises. “Demand for our products and services is increasing rapidly. We are in a growth phase and will seek additional talent in the future”, says Erika Gelfgren, CEO of Agrisera.
Umeå Biotech Incubator (UBI) is arranging a recruitment day with life science companies this May - and already 19 companies have signed up to take part. “We want students to get in touch with us. Recruitment opportunities are everything for life science companies”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.
The life science industry in the Umeå region is on track to triple its turnover and double the number of people it employs by 2030. To help it reach this target, the Swedish Agency for Economic and Regional Growth has awarded Umeå Biotech Incubator (UBI) a grant of SEK 9.5 million.
Umeå-based QureTech Bio AB receives support from the Swedish Research Council's major investment ENABLE-2, which in collaboration with Vinnova gives small and medium-sized companies access to the ENABLE-2 platform to continue development of new antibiotics.
Companies and alumni from Umeå Biotech Incubator (UBI) raised SEK 301 million in capital investment and grants in 2021 - a huge increase of SEK 243 million compared to the previous year. “It’s an absolutely fantastic amount. We work hard to help companies attract investment, so it is clear that our incubator process is working. Of the companies that raised money, 50 percent have a female CEO, whi
Umeå-based pharmaceutical company Vakona has signed an agreement with French company GTP Tech to initiate the first manufacturing steps of its acne medicine. “Production is at a level of quality that enables the medicine to be used in human clinical trials. If all goes well the medicine should be on the market within five to seven years”, says Mats Strömqvist, CEO and Chairman of the Board of Vak
Umeå Biotech Incubator (UBI) has strengthened its team with the appointment of two new business coaches - Lisandro Bernardo and Tobias Tovedal. “There’s significant demand right now for business support, both in the early and late phases of development. We are extremely happy to welcome these two stars to our team”, says Jennie Ekbeck, CEO of Umeå Biotech Incubator.
Ylva Elias has been appointed Business Development Manager at Swedish life science company UmanDiagnostics. She formerly took up her new position in January this year, and is responsible for selling and marketing UmanDiagnostics products throughout Europe.
Inficure Bio a life science company focused on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions co-presented with CymaBay Therapeutics positive data at the American Association for the study of Liver Diseases (AASLD) using the company’s proprietary NIF mouse model.
Omnio AB is developing new drug products based on the pro-inflammatory and immune regulatory effects of the serum protein plasminogen. During fall the company successfully raised 5.5 MSEK in a new share issue and welcomed four new investors to the company. The added investments make it possible for the company to now initiate its planned activities to develop recombinant plasminogen for treatment
The northern Sweden’s first networking pub for people working in the life science industry will open its doors in Umeå on November 23rd. Behind the initiative is Umeå Biotech Incubator, which has previously been named Europe’s most innovative life science incubator. “In Umeå we think it is important to ‘pay it forward’. We want to help and support one another and create a strong sense of unity an